We want to find better ways to support people suffering with mental health challenges, and we believe we’re onto something important.
Anorexia nervosa is a serious mental illness characterized by severe restriction of calorie intake and a preoccupation with weight and shape. Globally, about 2.2% of women and 0.3% of men suffer from anorexia nervosa at some point in their lives.1
An estimated 1 in 5 of people with anorexia nervosa do not recover or improve but go on to develop a long-term or chronic form of the condition.2
Anorexia nervosa also carries the highest mortality rate of all psychiatric disorders3 and currently, there is no approved pharmacological treatment option for those living with the condition.
Hear from the trial investigators…
Dr Walter Kaye, Professor of Psychiatry at the University of California San Diego School of Medicine, Department of Psychiatry Eating Disorders Program
Dr Kaye is leading the phase 2 clinical trial at the University of California San Diego School of Medicine. He also conducted an exploratory, open-label investigator-initiated study for anorexia nervosa in May 2022
Dr Hubertus Himmerich, Clinical Senior Lecturer in Eating Disorders at King’s College London and Consultant Psychiatrist at South London and Maudsley NHS Foundation Trust
Dr Himmerich is leading the phase 2 clinical trial at King's College London.
This will be the first study to use myPathfinder, COMPASS’ digital application for supporting patients throughout their COMP360 psilocybin journey. The app is optional for participants in the study, providing engaging education about the therapy model, and with participant consent, collecting real-world data for research on treatment responsiveness.